Bactesyn

Quick links to important sections

Bactesyn

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bactesyn

Property Description
Active Ingredient Sultamicillin
Form Tablets, Oral Suspension, Powder for Injection
Pharmacological Class Penicillin / beta-Lactamase Inhibitor Combination
Common Therapeutic Purpose Treatment of Systemic Bacterial Infections
Origin Synthetic (derived from penicillin)

Bactesyn is a synthetic, prescription-only medication featuring the active substance Sultamicillin, which is clinically recognized as a prodrug designed to enhance oral absorption compared to its non-esterified components. It belongs to the antibiotic class, specifically categorized as a penicillin / beta-lactamase inhibitor combination. This strategic dual-component structure positions Bactesyn as a modern, reliable therapeutic agent against bacterial infections.


What Type of Medicine is Bactesyn? (Classification and Origin)

Bactesyn is a combination product that delivers the benefits of two distinct agents. The active ingredient, Sultamicillin, is a synthetic molecule structurally derived from penicillin, engineered for high oral bioavailability. Sultamicillin splits into the antibiotic Ampicillin and the enzyme inhibitor Sulbactam, effectively overcoming common forms of bacterial resistance. This means the drug is purposefully designed to target infections, such as those of the respiratory tract or skin and soft tissues, where resistance to standard penicillins may be present.

The strategic combination of Ampicillin's ability to kill bacteria by disrupting cell wall synthesis with Sulbactam's protective action is a crucial differentiating factor from single-agent penicillins. Popular brands containing this same formulation, such as Unasyn, highlight the widespread clinical reliance on this particular combination to ensure antibiotic efficacy.


What Pharmaceutical Forms are Available?

Bactesyn is manufactured in various dosage forms to accommodate different administration methods across patient groups, including tablets and an oral suspension. The medication is also supplied as a sterile powder for injection, which is reconstituted into a solution for direct administration via the intravenous (IV) or intramuscular (IM) routes. Sultamicillin is recognized as an essential medicine with established efficacy for treating infections that require an antibiotic with this specific mechanism. The availability of both oral and parenteral forms is a key feature enabling treatment flexibility.

Regulatory References

  1. World Health Organization Essential Medicines List

What side effects are possible with Bactesyn?

Possible Side Effects and Safety Information

The safety profile of Bactesyn (Sultamicillin) is formally documented in government regulatory sources, which classify potential adverse events based on the affected System-Organ Class (SOC) and their observed frequency. The most frequently documented adverse reaction is Diarrhoea, which is classified as Very Common. Other reactions classified as Common include gastrointestinal effects such as Nausea, Vomiting, and Abdominal pain, alongside neurological effects like Headache and Dizziness.


Serious Adverse Reactions and Safety Constraints

Regulatory information specifies that rare but clinically significant adverse reactions must be considered. These include severe hypersensitivity reactions, such as Anaphylaxis, and severe cutaneous events (SCARs), like Stevens-Johnson Syndrome. The medication is formally Contraindicated in individuals with a known history of allergy to any penicillin or a history of beta-lactam-associated hepatic dysfunction.

Safety notes for specific populations are also documented. Since the active components are primarily cleared by the kidneys, patients with impaired renal function may require specific consideration due to prolonged elimination. Furthermore, periodic monitoring of the hematopoietic, renal, and hepatic systems is advised for therapy extending beyond fourteen days. Clostridium difficile-Associated Diarrhoea (CDAD) is a documented risk, which may occur during or after treatment is complete. The full range of safety information should be reviewed in the official prescribing documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for overdose with Bactesyn (ampicillin/sulbactam) highlights specific risks related to excessive drug exposure. An overdose may lead to neurological adverse reactions, with convulsions (seizures) being the primary documented manifestation associated with high levels of beta-lactam drugs in the central nervous system.

Overdose risk is elevated in certain patient populations. Since the drug components are primarily eliminated through the kidneys, patients with impaired renal function are at a higher risk of toxicity due to a prolonged half-life and accumulation of the drug in the body.


Emergency Response and Management

Overdose Symptom Clusters Key Regulatory Action
Neurological symptoms, including seizures Seek immediate emergency medical attention or call poison control.
Signs of severe hypersensitivity (e.g., trouble breathing, swelling) Immediate emergency treatment is required, including supportive measures like epinephrine and oxygen.

In the event of a suspected overdose, the primary management strategy focuses on providing immediate supportive care. Although one component, sulbactam, is removable by hemodialysis, regulatory documents state there is limited clinical information regarding the effectiveness of hemodialysis as a treatment for overdosage. It is crucial to seek emergency medical help immediately if an overdose is suspected, regardless of whether symptoms are currently present.

Therapeutic Uses of Bactesyn

Bactesyn (Sultamicillin) is commonly used to help with conditions associated with acute or disruptive episodes caused by susceptible bacteria across key body systems. Its use is relevant for a wide array of conditions presenting with significant symptomatic burden.

The medication is applied across domains where additional symptomatic support is needed, including severe infections of the respiratory tract (like bacterial pneumonia and sinusitis), skin and soft tissues (such as cellulitis and abscesses), and urinary tract infections. It is particularly relevant for managing infections where bacteria show resistance to standard penicillin-class treatments.

Quick Fact: Relief for Symptoms Related to Inflammatory or Irritative States

Its application helps address symptom clusters that may become intense or disruptive, such as fever, swelling, and localized pain. It provides support that helps maintain a sense of stability when symptoms are more noticeable, assisting with maintaining functional stability. It is often applied during phases of recovery, such as when using an oral formulation for continuation therapy.

Regulatory References

  1. NCBI Bookshelf FDA-Approved Indications on Ampicillin/Sulbactam

Eligibility and Restrictions for Use

The eligibility for using Bactesyn (Sultamicillin) is defined by regulatory authorities based on penicillin-class restrictions and the specific components of the medicine.

Contraindicated Populations

Bactesyn must not be used by individuals with a known history of allergic reaction to any penicillin, or by patients with Infectious Mononucleosis (glandular fever). A history of cholestatic jaundice or hepatic dysfunction associated with the prior use of ampicillin/sulbactam also constitutes a non-eligibility rule.

Classification Population Restriction
Absolute Contraindication Hypersensitivity to penicillins or sulbactam; Infectious Mononucleosis.
Formulation Restriction Specific hereditary metabolic disorders (e.g., certain sugar intolerances) [1.1].

Restricted or Conditional Use

Use is restricted in several population groups, requiring special consideration:

  • Organ Function: Patients with severe renal impairment must have their administration frequency modified, as the drug's elimination is impaired. Caution is advised for patients with evidence of hepatic dysfunction [1.2].
  • Age: While established for adults and children 30 kg, safety and efficacy are not established in neonates and preterm infants [1.3].
  • Reproductive Status: Use during pregnancy is conditional, allowed only if the potential benefits outweigh the potential risk [1.4]. Use in nursing mothers is not recommended as the components pass into breast milk.

What should I know about interactions with other medicines?

The official regulatory profile for Bactesyn (Sultamicillin, a prodrug of Ampicillin and Sulbactam) details several documented interaction patterns with other medicines and substances.

Interactions Affecting Drug Exposure

Co-administration with Probenecid is documented to interfere with the kidney's elimination process, specifically reducing the renal tubular secretion of Ampicillin and Sulbactam. This interference results in increased and prolonged serum concentrations of the active components. Conversely, the use of Bactesyn with Methotrexate has been reported to cause a decreased clearance of Methotrexate, leading to the potential for increased Methotrexate toxicity.

Pharmacodynamic and Efficacy Interference

Bactesyn’s bactericidal action may be antagonized by certain Bacteriostatic Agents (such as Tetracyclines or Chloramphenicol), as co-administration may interfere with the drug’s intended effectiveness. In addition, the penicillin component can alter coagulation tests, and this effect may be additive when used alongside Anticoagulants (like Warfarin). The official prescribing information also cites case reports suggesting that Estrogen-Containing Oral Contraceptives may have reduced effectiveness when combined with the Ampicillin component.

Interaction-Related Restrictions

Co-administration with Allopurinol substantially increases the documented incidence of rash. Furthermore, Bactesyn is formally contraindicated in patients with Infectious Mononucleosis due to the high risk of a widespread maculopapular rash associated with Ampicillin-class drugs. No mandatory timing separation between doses is specified in the official documentation.

Mechanism of Action

The mechanism of Bactesyn is defined by the synergistic action of its two active components, Ampicillin and Sulbactam, which are released from the prodrug Sultamicillin. This mechanism involves counteracting bacterial defense enzymes while concurrently disrupting cell wall integrity.


Dual-Action Inhibition of Bacterial Enzymes

The drug acts by engaging two critical bacterial targets: the Penicillin-Binding Proteins (PBPs) and the beta-Lactamase Enzymes. Ampicillin component acts as an irreversible inhibitor of PBPs, permanently blocking the final step of peptidoglycan cross-linking needed for a strong bacterial cell wall. Sulbactam, in parallel, acts as an irreversible suicide inhibitor against beta-lactamase enzymes, neutralizing the activity of bacterial beta-lactamase enzymes.


Mechanistic Synergy and Cell Wall Destruction Cascade

The synergy ensures that Sulbactam protects the Ampicillin from enzymatic degradation, which allows the antibiotic to reach its target more effectively. This coordinated action—enzyme protection and structural destruction—triggers a cascade where the structurally defective cell wall cannot withstand the high internal osmotic pressure, leading to autolysis and a bactericidal effect. This mechanism is defined by its ability to neutralize specific types of enzymatic resistance.

Dosage and Administration Information

How to Use Bactesyn

Bactesyn (Sultamicillin) is primarily administered via the oral route, available as tablets and a powder for oral suspension. This oral form is often used as continuation therapy following initial intravenous or intramuscular treatment with its component combination.


Administration Scope and Dosing

Standard adult dosing typically ranges from 375 mg to 750 mg (Sultamicillin equivalent), administered twice daily (every 12 hours). The medicine may be taken with or between meals, as food intake does not significantly affect its systemic absorption. For the single-dose regimen used for uncomplicated gonorrhea, 2.25 g is administered concomitantly with 1.0 g Probenecid.

Procedural Instructions and Special Conditions

For proper intake, tablets must be swallowed whole and should not be crushed. They should be taken while in an upright position with an adequate amount of fluid. If the oral suspension is used, the liquid must be shaken well prior to each administration.

Treatment duration is defined by the specific infection, generally lasting 5 to 14 days, but must continue until 48 hours after fever and other abnormal signs of infection have resolved. For infections caused by beta-hemolytic streptococci, there is a minimum duration of 10 days.

Population-Specific Rules

Dose modification applies to specific populations. Pediatric dosing for children weighing 30 kg or less is calculated based on weight. For patients with severe renal impairment (CrCl le 30 mL/min), the administration interval is adjusted to be less frequent.

Recent Clinical Evidence

Research evidence / Overview of studies for Bactesyn

The available scientific evidence on Bactesyn (Sultamicillin) utilizes controlled clinical trials, systematic reviews, and meta-analyses. This research was studied to explore how patient status changes in the context of various bacterial infections and to track specific outcomes related to systemic or functional imbalance during the defined study periods. The evidence base describes patterns observed in specific groups of patients under controlled conditions.


Evidence for Use in Respiratory Tract Infections

Research on Bactesyn for respiratory tract infections, such as bacterial pneumonia, sinusitis, and middle ear infections (otitis media), utilizes evidence from Randomized Controlled Trials (RCTs) and larger Systematic Reviews. These studies were used to explore short-term changes in patient status and often included comparisons against other standard antibiotic treatments to measure relative outcomes.

The trials were designed to examine two main types of outcomes: clinical outcomes (how symptoms, such as fever or pain, changed, or were measured in the study) and microbiological outcomes (the measurements of the presence of the bacteria causing the infection). Findings describe patterns observed in the studies, including measurements of outcomes related to physical discomfort tracked during the study period. What remains uncertain is the full picture of long-term patient status after the immediate post-treatment follow-up, as evidence related to long-term functional stability and recurrence of symptoms over extended periods are not fully established.


Evidence for Use in Skin and Soft Tissue Infections

For skin and soft tissue infections (SSTIs), the evidence was evaluated in Comparative Clinical Trials and RCTs. These studies were conducted during periods of increased symptom activity and applied in research contexts involving fluctuating or unstable symptoms. Studies monitored outcomes linked to inflammatory or irritative states, focusing on measurements of outcomes reflecting daily functioning or activity level (e.g., assessment of wound status) and rates of symptom return following treatment. Some studies reported findings were mixed related to functional stability and symptom return.


Evidence for Use in Urinary Tract and Systemic Infections

Bactesyn was studied for conditions associated with acute or disruptive episodes, such as Urinary Tract Infections (UTIs), through Controlled Clinical Trials. Research describes patterns related to short-term outcomes related to systemic or functional imbalance in adults and older adults. Research describes differences in the patterns of outcomes related to systemic or functional imbalance measured between the initial assessment and the later follow-up.

For more complex or systemic infections, such as those within the abdomen, bone, or joint, evidence was evaluated in specialized clinical trials. The available evidence for specific complicated sites like bone and joint infections is limited compared to the more common indications.

Key Studies & References

  1. Sultamicillin (CP-49, 952): evaluation of two dosage schedules in urinary infection (UTI/Geriatric Population Study with Follow-up)
  2. WHO Model List of Essential Medicines (Reference for Ampicillin + Sulbactam status)

Frequently Asked Questions (FAQ)

Common questions about Bactesyn (FAQ)

Q: What is the expected duration of action for a dose of Bactesyn?

Official information indicates that the active components of Bactesyn, ampicillin and sulbactam, have a relatively short elimination half-life (t1/2) of approximately one hour after it is administered. The half-life refers to the time it takes for half of the drug to be cleared from the system. This short duration is consistent with the established dosing interval.


Q: Can Bactesyn affect sleep patterns?

Regulatory documents list central nervous system effects such as dizziness and headache as common side effects of Bactesyn. While changes to sleep patterns are not explicitly listed in the common side effects, these known neurological effects may indirectly affect rest or concentration.


Q: Is there a known interaction between Bactesyn and alcohol consumption?

Regulatory sources generally advise caution when using Bactesyn with alcohol. In some cases, consuming alcohol while taking this class of medication may worsen specific side effects, such as stomach upset or dizziness.


Q: Is Bactesyn the same as [Name of Competitor Drug]?

Bactesyn is a brand name for the active substance Sultamicillin, which is a prodrug of Ampicillin and Sulbactam. Other brand names exist for the same formulation, meaning they contain the same active ingredients. The generic name for the active drug substance is Sultamicillin.


Q: Are there any long-term safety concerns associated with taking Bactesyn?

Official guidance addresses safety for extended use. For any course of therapy extending beyond 14 days, official documents advise periodic monitoring of organ systems, including the kidneys (renal), liver (hepatic), and blood-forming systems (hematopoietic).


Q: Does Bactesyn cause fatigue or dizziness in most users?

Official regulatory documents classify dizziness as a common side effect of Bactesyn. However, fatigue is generally not listed in the common or very common categories of documented side effects.


Q: What signs might indicate a user is experiencing an unusual or serious side effect from Bactesyn?

Official product information emphasizes the risk of severe, though rare, reactions. These include severe allergic reactions such as anaphylaxis and serious skin conditions like Stevens-Johnson Syndrome (SJS). Regulatory warnings indicate the need to be aware of these documented safety risks.


Q: What is the general recommendation for Bactesyn use in elderly patients?

Regulatory information indicates that dosage modification is not typically required for elderly patients who have normal kidney function. However, the clearance of the medicine may be slightly slower in older adults, which is a consideration for patients with existing kidney issues.


Q: What are the known components (active and inactive ingredients) of Bactesyn?

The medicine is a combination product containing the active components Ampicillin and Sulbactam, which are delivered via the prodrug Sultamicillin. The complete list of inactive ingredients, which can vary by manufacturer and formulation, can be found in the full prescribing information for your specific product.


Q: Is Bactesyn considered a broad-spectrum medicine?

Yes, regulatory and pharmacological sources often describe one of its active components, Ampicillin, as a broad-spectrum semisynthetic penicillin. When combined with Sulbactam, the product’s spectrum of activity is effectively extended to fight bacteria that are resistant to standard penicillins.


Q: What happens if a person forgets to take a dose of Bactesyn?

Regulatory documents outline procedures for a missed dose. This typically involves taking the missed dose if remembered quickly, or skipping it if the next dose is due soon, to maintain the prescribed schedule. Specific guidance is defined in the product information.


Q: What information is usually required before a doctor prescribes Bactesyn?

Official safety warnings require health professionals to make a careful inquiry concerning previous allergic reactions to penicillins, cephalosporins, or other related antibiotic agents before starting therapy. This procedural step is necessary due to the medication’s class restrictions.


Q: Can Bactesyn affect the results of common lab tests?

Official documents note that the penicillin component of Bactesyn has been reported to alter coagulation test results. The impact on other routine laboratory tests is typically detailed in the specialized prescribing information for healthcare providers.


Q: Are there any known warnings related to driving or operating heavy machinery while on Bactesyn?

Official product information sometimes advises caution regarding tasks that require concentration. While some sources state there are no known effects, other official documents contain a caution that individuals experiencing side effects that affect concentration, such as dizziness, are advised to avoid driving or operating machinery.


Q: Is it possible to become dependent on Bactesyn?

According to official monographs for the drug, Bactesyn is classified as a Non-Habit Forming medication. It is an antibiotic used to treat bacterial infections.


Q: How long does Bactesyn stay in the system after the last dose?

Based on pharmacokinetics data, the active components of the drug have an elimination half-life (t1/2) of approximately one hour after the last oral dose. It takes multiple half-lives for the drug to be fully cleared from the system.


Q: Does taking Bactesyn require a special diet?

Official guidance notes that the medicine can be taken with or between meals. Food intake has not been documented to significantly affect the systemic absorption of the drug.


Q: What should a person tell their pharmacist when picking up Bactesyn?

Official warnings specify that a review of previous allergic reactions to penicillins or related antibiotics is required before starting this therapy. This information is critical for the pharmacist and prescribing physician to consider.


Q: What does the term 'contraindication' mean in the context of Bactesyn?

A contraindication is a condition or factor that significantly increases the risk of harm, making it necessary to avoid the use of the medicine. For Bactesyn, examples of contraindications include a known allergy to penicillin or a diagnosis of Infectious Mononucleosis.


Q: Why are there different strengths of Bactesyn available?

Different strengths of Bactesyn are manufactured to accommodate the different dosing requirements needed for effective treatment. These requirements vary based on the specific type of infection being treated, as well as the patient's age and weight (particularly for pediatric dosing).


Q: Is Bactesyn sometimes used for preventative care?

Official regulatory documents define the purpose of Bactesyn as the treatment of established bacterial infections. It is not listed or prescribed for general preventative care (prophylaxis) based on the current approved labeling.


Q: What is the recommended approach if a person has a strong side effect from Bactesyn?

Official product information specifies that, in the event of an allergic reaction, the medicine must be immediately discontinued. For any severe or concerning reaction, official safety warnings indicate that prompt medical assessment or emergency care is required.


Q: What is the difference between the brand name and the generic version of Bactesyn?

Bactesyn is a brand name used for the medicine. The internationally recognized generic name for the active substance is Sultamicillin, which delivers the combination of ampicillin and sulbactam. Both the brand name and the generic product contain the same active components.

How should Bactesyn be stored and disposed of?

How to Store and Dispose of Bactesyn

Bactesyn (Sultamicillin) requires specific environmental controls as detailed in regulatory documents to maintain its stability.


Official Storage Requirements

Requirement Description
Temperature Store at a temperature below 30 C (86 F).
Protection The product must be protected from light and moisture and kept in a cool, dry place.
Container Keep the medicine in its tightly closed, original container.
Child Safety Must be stored out of the sight and reach of children.

Disposal and Stability

The shelf-life of the product depends on maintaining these required storage conditions. For the powder for injection or oral suspension, stability is limited after mixing, and the specific use-by time detailed in the prescribing information must be followed.

Disposal of unused or expired Bactesyn must follow official guidelines. Federal and local regulations mandate prioritizing drug take-back programs or mail-back envelopes over disposal in the household trash. The medicine must not be flushed down the toilet or sink, as this is restricted by environmental disposal rules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bactesyn found in:

A-Z Index: